Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesA phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
Cancer Chemotherapy and Pharmacology, 10/29/09
Cohen SJ et al. – The recommended phase II dose of imexon is 875 mg/m^2 with gemcitabine 1,000 mg/m^2. DLT was acute abdominal pain and cramping. Encouraging antitumor responses support further evaluation of this combination in advanced pancreatic cancer.
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer
Annals of Internal Medicine, 11/17/09
Current status of maintenance therapy for advanced ovarian cancer
International Journal of Women's Health, 11/03/09
Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations
Cancer Management and Research, 11/05/09
Sponsor
Article Search
Sponsor